Evolent HealthNYSE: EVH

Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Despite setbacks, Evolent secured record-breaking new business deals and anticipates over 15% annual revenue growth, driven by rate increases and strategic partnerships. EVH stock appears undervalued with a P/E ratio of 16.57, suggesting a potential contrarian buy opportunity given its long-term growth prospects.

Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Kevin Caliendo - UBS Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter Ended September 30, 2024.

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago.

Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company to Participate in Upcoming Conferences WASHINGTON , Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.

Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but potential bidding wars may drive up the stock price further. Evolent's current valuation at 21x forward free cash flow may undervalue the company, potentially leading to higher bids in the future.

Evolent Health is in talks with private equity firms and other companies for a potential sale, in a process that kicked off after the healthcare services provider received inbound interest, people familiar with the matter said on Thursday.